{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/immunitybio-ibrx/",
 "dataUrl": "https://clearank.com/stock/immunitybio-ibrx/data.json",
 "title": "ImmunityBio (IBRX) Stock Forecast & Price Target (2026)",
 "description": "IBRX stock forecast and price target 2026: is ImmunityBio a buy? One of the biotechnology names we cover. Wall Street's median target is $14.50.",
 "headline": "ImmunityBio Inc. (IBRX)",
 "published": "2026-11-09T12:30:44+00:00",
 "modified": "2026-11-11T12:46:39.523+00:00",
 "generated": "2026-11-11T13:24:37.763Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by Anthony Beachey, Financial Journalist; prices delayed by up to a minute.",
 "asset": {
  "ticker": "IBRX",
  "name": "ImmunityBio Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://immunitybio.com"
 },
 "quote": {
  "price": 6.75,
  "previousClose": 7.11,
  "change": -0.365,
  "changePercent": -5.13,
  "open": 6.98,
  "high": 7.27,
  "low": 6.61,
  "volume": 20007100,
  "averageVolume": 13501340,
  "marketCap": 7175506862,
  "fiftyTwoWeekHigh": 12.43,
  "fiftyTwoWeekLow": 1.95,
  "marketOpen": false,
  "asOf": "2026-11-11T12:46:39.000Z"
 },
 "statistics": {
  "pe": -7.03,
  "eps": -0.96,
  "dividendYield": 0,
  "beta": 0.174,
  "priceToSales": 39.3023,
  "priceToBook": -6.772792282203128,
  "revenueTtm": 182572000,
  "grossMargin": 0.994184231069477,
  "returnOnEquity": null
 },
 "technicals": {
  "rsi": 36.56,
  "macd": -0.3739,
  "sma50": 8.7,
  "sma200": 7.97,
  "rsiSignal": "Bearish",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 39,
  "consensus": "Sell",
  "fairValue": null,
  "analystTarget": 14.5,
  "analystCount": 4,
  "wallStreetConsensus": "Strong Buy",
  "generatedAt": "2026-11-11T12:46:39.000Z",
  "priceAtAnalysis": 6.745,
  "volatility": {
   "daily": 6.28,
   "risk": "volatile"
  }
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 3.64,
    "base": 6.91,
    "upside90th": 13.12
   },
   {
    "year": 2028,
    "downside10th": 2.86,
    "base": 7.08,
    "upside90th": 17.53
   },
   {
    "year": 2029,
    "downside10th": 2.39,
    "base": 7.26,
    "upside90th": 22.02
   },
   {
    "year": 2030,
    "downside10th": 2.06,
    "base": 7.44,
    "upside90th": 26.79
   }
  ]
 },
 "faqCount": 7,
 "atAGlance": {
  "asOf": "November 10, 2026",
  "rating": "Sell",
  "score": 39,
  "evidence": [
   {
    "label": "Trend",
    "text": "Mixed: the price is below both its 50- and 200-day moving averages, though the 50-day is still above the 200-day ($8.70 and $7.97)."
   },
   {
    "label": "Earnings",
    "text": "IBRX beat estimates in 3 of its last 8 quarters, yet fell in the first session after 1 of those beats."
   },
   {
    "label": "Insiders",
    "text": "Insiders sold $9.4M and made no open-market purchases over the last 18 months."
   }
  ]
 },
 "figures": {
  "asOf": "November 10, 2026",
  "earningsReaction": {
   "quarters": 8,
   "beats": 3,
   "fellFirstSessionAfterBeat": 1,
   "latestReport": "Nov 9, 2026",
   "latestSurprisePercent": -80,
   "latestFirstSessionMovePercent": -5.13
  },
  "insiders": {
   "windowMonths": 18,
   "soldValue": 9400689,
   "boughtValue": 0,
   "sales": 12,
   "purchases": 0,
   "note": "open-market transactions only; grants and option exercises excluded"
  },
  "drawdown": {
   "years": 10,
   "worstFallPercent": -96.52,
   "peak": "February 2021",
   "trough": "October 2023",
   "recoveredBy": null,
   "recoveryMonths": null,
   "belowThatPeakNowPercent": -82.76,
   "fromHighNowPercent": -82.76,
   "oneYearHoldsPositivePercent": 42,
   "dividendsReinvested": false
  },
  "seasonality": {
   "years": 10,
   "bestMonth": {
    "month": "Jan",
    "averagePercent": 24.4,
    "upYearsPercent": 50
   },
   "worstMonth": {
    "month": "Aug",
    "averagePercent": -11.08,
    "upYearsPercent": 20
   }
  },
  "correlations": null,
  "analystTargets": {
   "analysts": 4,
   "low": 12,
   "median": 14.5,
   "high": 16,
   "mean": 14.25,
   "buy": 4,
   "hold": 0,
   "sell": 0
  },
  "dividend": null,
  "simulation": {
   "year": 2030,
   "base": 7.44,
   "percentile10": 2.06,
   "percentile90": 26.79,
   "note": "Monte Carlo simulation outcomes, not price targets"
  }
 },
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "ch-overview",
   "title": "IBRX stock today, November 11, 2026: price, news and analyst targets",
   "text": [
    "As of November 10, 2026, ImmunityBio Inc. (IBRX) trades at $6.75. Wall Street's median 12-month price target is $14.50 across 4 analysts, 115.0% above the price. CleaRank rates it Sell with a score of 39/100.",
    "ImmunityBio's stock has fallen sharply over the past month, down 35.82%, and sits 22.43% below its 50-day average and 15.33% below its 200-day average. The slide follows a November 9, 2026 quarterly report in which adjusted EPS of -$0.09 missed the analysts' estimate of -$0.05, and the stock fell 5.13% in the next session. Revenue still grew 52.30% year on year, but the company remains far from profit: its net profit margin is -607.79%. CleaRank rates the stock Sell with a score of 39/100, more cautious than the Strong Buy consensus from the four analysts who cover it, all of whom rate it Buy. The gap between those two views is the central question for the stock now.",
    "The stock fell 5.13% in the first session after the November 9, 2026 report, when adjusted EPS came in at -$0.09 against an analyst estimate of -$0.05, a miss of 80.00%. It was the company's third miss in the last four reports, and the pattern matters for how investors weigh the rest of the record. Of the eight recent reports, only three beat the EPS estimate, and only one of those beats was followed by a lower share price. The August 4, 2026 report also missed badly, with EPS of -$0.22 against -$0.08 expected, and the stock rose 4.32% the next session. Earnings reactions have been inconsistent, so the November drop is one data point rather than a settled pattern.",
    "Analysts expect revenue this fiscal year to reach $226.6M, a rise of 100.0%. Growth on that scale is the core of the bull case. Against it stand losses that are large relative to sales: the operating margin is -159.68% and the net profit margin is -607.79%. The GAAP EPS over the last twelve months is -$0.96, and the analysts' average estimate for this fiscal year is -$0.92. Revenue growth is real, but the company still spends far more than it takes in.",
    "At a market capitalisation of $7.2B and a price-to-sales ratio of 39.30, the stock trades at more than ten times the sector median price-to-sales of 3.4. With no profit to measure against, the premium rests entirely on expected growth. Insiders sold $9.4M of stock over the last 18 months across 12 sales, and recorded no open-market purchases over the same period. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than purchases would be, but the absence of any buying by insiders is worth noting.",
    "The stock is below both its 50-day simple moving average of $8.70 and its 200-day simple moving average of $8.00 at $7.97, and the 50-day average remains 9.16% above the 200-day average. The 14-day RSI of 36.6 sits in the bearish zone, and the MACD line is negative. Over one month the stock is down 35.82% and over one week it is down 18.64%, while the one-year return of 212.27% shows how much of the stock's rise came before the recent slide. The stock is still well above its 52-week low of $1.95, so the year's gains have not been erased, but the recent direction is clearly down.",
    "CleaRank score 39/100 (Sell). 4 of 17 checks pass: trend 1 of 4, momentum 1 of 3, valuation and quality 0 of 3, analysts 2 of 3, track record 0 of 4.",
    "ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases."
   ]
  },
  {
   "id": "ch-news",
   "title": "IBRX stock news",
   "text": [
    "November 9, 2026·Earnings report",
    "The November 9, 2026 report showed adjusted EPS of -$0.09 against a -$0.05 estimate, and the stock fell 5.13% in the next session. A second consecutive miss would reinforce doubts about the company's path to lower losses.",
    "October 15, 2026·Jefferies",
    "Jefferies reaffirmed its Buy rating on October 15, 2026, adding to a set of four current Buy ratings across the covering analysts. Continued support from a major firm after the stock's slide keeps the Street's positive stance intact.",
    "October 15, 2026·HC Wainwright & Co.",
    "HC Wainwright & Co. kept its Buy rating on October 15, 2026, the same day as Jefferies. It has now reaffirmed Buy on three separate dates this year, including June 2 and May 20, 2026.",
    "BTIG kept its Buy rating on May 21, 2026. The reiteration adds to the consensus of four Buy ratings and gives the analysts' positive view a longer track record in 2026."
   ],
   "lists": {
    "items": [
     "Earnings miss and share drop November 9, 2026·Earnings report The November 9, 2026 report showed adjusted EPS of -$0.09 against a -$0.05 estimate, and the stock fell 5.13% in the next session. A second consecutive miss would reinforce doubts about the company's path to lower losses.",
     "Jefferies keeps Buy rating October 15, 2026·Jefferies Jefferies reaffirmed its Buy rating on October 15, 2026, adding to a set of four current Buy ratings across the covering analysts. Continued support from a major firm after the stock's slide keeps the Street's positive stance intact.",
     "HC Wainwright reiterates Buy October 15, 2026·HC Wainwright & Co. HC Wainwright & Co. kept its Buy rating on October 15, 2026, the same day as Jefferies. It has now reaffirmed Buy on three separate dates this year, including June 2 and May 20, 2026.",
     "BTIG maintains Buy May 21, 2026·BTIG BTIG kept its Buy rating on May 21, 2026. The reiteration adds to the consensus of four Buy ratings and gives the analysts' positive view a longer track record in 2026."
    ]
   }
  },
  {
   "id": "ch-street",
   "title": "IBRX price target 2026",
   "text": [
    "The base case is that the stock keeps trading below its moving averages until it shows either a narrower loss or a sustained recovery in trend. For that to change, the price would need to reclaim the 200-day average at $7.97 and then the 20-day EMA at $8.34, which would be the first signs that selling pressure is easing. Analysts' median 12-month target of $14.50 sits well above the current price, with a range from $12.00 to $16.00, and all four firms reaffirmed Buy ratings as recently as October 15, 2026. Those targets only become meaningful if the company narrows its losses, since the analysts' average EPS estimate for this fiscal year is -$0.92 and the stock's negative earnings keep the valuation stretched, with a price-to-sales ratio of 39.30 against a sector median of 3.4. A further fall through the 52-week low at $1.95 would contradict the current trend and would likely reflect a sharp loss of confidence. Simulations from past volatility are not forecasts, and the stock's typical daily move of 6.28% means large swings are normal here."
   ],
   "tables": [
    {
     "caption": "Recent analyst rating actions on IBRX",
     "columns": [
      "Date",
      "Firm",
      "Action",
      "Rating"
     ],
     "rows": [
      {
       "label": "Oct 15, 2026",
       "cells": [
        "Jefferies",
        "Maintains",
        "Buy"
       ]
      },
      {
       "label": "Oct 15, 2026",
       "cells": [
        "HC Wainwright & Co.",
        "Reiterates",
        "Buy"
       ]
      },
      {
       "label": "Jun 2, 2026",
       "cells": [
        "HC Wainwright & Co.",
        "Reiterates",
        "Buy"
       ]
      },
      {
       "label": "May 21, 2026",
       "cells": [
        "BTIG",
        "Reiterates",
        "Buy"
       ]
      },
      {
       "label": "May 20, 2026",
       "cells": [
        "HC Wainwright & Co.",
        "Reiterates",
        "Buy"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-levels",
   "title": "IBRX support and resistance levels",
   "text": [
    "Support sits at the 52-week low of $1.95, the nearest level below the price and a long way down, which marks the bottom of the stock's one-year range. Resistance comes first at the 200-day simple moving average of $7.97, the nearest level above the price, followed by the 20-day exponential moving average at $8.34 and the 50-day simple moving average at $8.70. The 52-week high of $12.43 is the furthest level above. Because the price is below all of these averages, a rally would have to clear $7.97 and $8.34 before the trend picture improves."
   ],
   "tables": [
    {
     "caption": "IBRX support and resistance levels",
     "columns": [
      "Level",
      "What it is",
      "Price",
      "From the price"
     ],
     "rows": [
      {
       "label": "Resistance 4",
       "cells": [
        "52-week high",
        "$12.43",
        "+84.3%"
       ]
      },
      {
       "label": "Resistance 3",
       "cells": [
        "50-day moving average",
        "$8.70",
        "+28.9%"
       ]
      },
      {
       "label": "Resistance 2",
       "cells": [
        "20-day exponential average",
        "$8.34",
        "+23.6%"
       ]
      },
      {
       "label": "Resistance 1",
       "cells": [
        "200-day moving average",
        "$7.97",
        "+18.1%"
       ]
      },
      {
       "label": "Price",
       "cells": [
        "November 10, 2026",
        "$6.75",
        ""
       ]
      },
      {
       "label": "Support 1",
       "cells": [
        "52-week low",
        "$1.95",
        "-71.1%"
       ]
      }
     ]
    }
   ],
   "lists": {
    "items": [
     "RSI Bearish",
     "SMA cross Bullish",
     "Price vs SMA Bearish",
     "MACD Bearish"
    ]
   }
  },
  {
   "id": "ch-price",
   "title": "IBRX stock price and trading"
  },
  {
   "id": "ch-fundamentals",
   "title": "IBRX fundamentals and valuation",
   "text": [
    "Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, IBRX trades at 39.30x, far above the sector median of 3.40x.",
    "Return vs XLV: Since May 30, 2025, IBRX has gained 153.6% against a gain of 42.4% for XLV.",
    "Revenue growth: Revenue grew 668.3% in FY2025 to $113M, from $14.7M a year earlier.",
    "Profit margin: The net margin was -310.2% in FY2025, up from -2,805.3% the year before.",
    "Loss-making: IBRX lost $351M in FY2025.",
    "Earnings record: IBRX beat the analyst estimate in 3 of the last 8 quarters.",
    "Market reaction: The stock fell in the first session after 1 of those 3 beats, so a beat has not been enough on its own."
   ],
   "tables": [
    {
     "caption": "IBRX earnings surprises and the stock's reaction",
     "columns": [
      "Report",
      "Estimate",
      "Actual",
      "Surprise",
      "First sessionDay 1",
      "5 sessionsDay 5"
     ],
     "rows": [
      {
       "label": "Nov 9, 2026",
       "cells": [
        "-$0.05",
        "-$0.09",
        "-80.00%",
        "-5.13%",
        "-"
       ]
      },
      {
       "label": "Aug 4, 2026",
       "cells": [
        "-$0.08",
        "-$0.22",
        "-175.00%",
        "+4.32%",
        "+9.35%"
       ]
      },
      {
       "label": "May 7, 2026",
       "cells": [
        "-$0.07",
        "-$0.08",
        "-14.29%",
        "+9.66%",
        "+5.03%"
       ]
      },
      {
       "label": "Feb 23, 2026",
       "cells": [
        "-$0.10",
        "-$0.06",
        "+40.00%",
        "+17.50%",
        "+6.21%"
       ]
      },
      {
       "label": "Nov 5, 2025",
       "cells": [
        "-$0.10",
        "-$0.07",
        "+30.00%",
        "-1.40%",
        "-4.19%"
       ]
      },
      {
       "label": "Aug 5, 2025",
       "cells": [
        "-$0.10",
        "-$0.10",
        "+0.00%",
        "-1.24%",
        "+2.49%"
       ]
      },
      {
       "label": "May 12, 2025",
       "cells": [
        "-$0.14",
        "-$0.15",
        "-7.14%",
        "+6.36%",
        "+18.64%"
       ]
      },
      {
       "label": "Mar 3, 2025",
       "cells": [
        "-$0.13",
        "-$0.08",
        "+38.46%",
        "+5.96%",
        "+2.11%"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-history",
   "title": "IBRX price history and drawdowns",
   "text": [
    "Against the market: IBRX trailed the S&P 500 over this period: $10,827 against $39,967.",
    "A $10,000 investment in IBRX in December 2016 would be worth about $10,827 today, compared with about $39,967 for the same investment in the S&P 500 benchmark with its dividends reinvested."
   ]
  },
  {
   "id": "ch-scenarios",
   "title": "IBRX stock price prediction 2030",
   "text": [
    "CleaRank's simulation projects a price near $7.44 for IBRX by 2030 in the base case, from $6.75 today (1.1x over 4 years). The 10th-percentile path ends near $2.06. These are outcomes of a Monte Carlo simulation run on IBRX's historical return distribution, not price targets, and they assume no dividends are reinvested."
   ],
   "tables": [
    {
     "caption": "IBRX simulated price paths by year",
     "columns": [
      "Year",
      "10th percentile",
      "Base case",
      "90th percentile",
      "range base today"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$3.64",
        "$6.91",
        "$13.12",
        ""
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$2.86",
        "$7.08",
        "$17.53",
        ""
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$2.39",
        "$7.26",
        "$22.02",
        ""
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$2.06",
        "$7.44",
        "$26.79",
        ""
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-insiders",
   "title": "IBRX insider trading",
   "text": [
    "Net insider selling: No insider bought IBRX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would."
   ],
   "tables": [
    {
     "caption": "Insider transactions in IBRX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Oct 5, 2026",
       "cells": [
        "Barry J. Simon, M.D. Director",
        "Sell",
        "25.0K",
        "$268.8K"
       ]
      },
      {
       "label": "Oct 2, 2026",
       "cells": [
        "Cheryl L Cohen Director",
        "Sell",
        "81.1K",
        "$851.1K"
       ]
      },
      {
       "label": "Oct 2, 2026",
       "cells": [
        "Cheryl L Cohen Director",
        "Option",
        "56.0K",
        "$166.8K"
       ]
      },
      {
       "label": "Jul 2, 2026",
       "cells": [
        "Cheryl L Cohen Director",
        "Sell",
        "131.2K",
        "$1.2M"
       ]
      },
      {
       "label": "Jul 2, 2026",
       "cells": [
        "Cheryl L Cohen Director",
        "Option",
        "56.0K",
        "$166.8K"
       ]
      },
      {
       "label": "Jul 1, 2026",
       "cells": [
        "Christobel E. Selecky Director",
        "Sell",
        "159.5K",
        "$1.4M"
       ]
      },
      {
       "label": "Jul 1, 2026",
       "cells": [
        "Christobel E. Selecky Director",
        "Option",
        "159.5K",
        "$476.5K"
       ]
      },
      {
       "label": "Jun 30, 2026",
       "cells": [
        "Christobel E. Selecky Director",
        "Sell",
        "96.7K",
        "$871.2K"
       ]
      },
      {
       "label": "Jun 30, 2026",
       "cells": [
        "Christobel E. Selecky Director",
        "Option",
        "96.7K",
        "$284.4K"
       ]
      },
      {
       "label": "Jun 24, 2026",
       "cells": [
        "Barry J. Simon, M.D. Director",
        "Sell",
        "25.0K",
        "$196.9K"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-faq",
   "title": "IBRX stock forecast: questions people ask",
   "text": [
    "How these figures are computed, and where the data comes from: CleaRank methodology."
   ]
  },
  {
   "id": "ch-related",
   "title": "Compare IBRX with similar assets",
   "links": [
    {
     "text": "TEVA Teva Pharmaceutical Industries Ltd. NYSE $42.40 -1.33%",
     "url": "https://clearank.com/stock/teva-pharmaceutical-teva/"
    },
    {
     "text": "DHR Danaher Corp. NYSE $236.11 +0.42%",
     "url": "https://clearank.com/stock/dhr-stock-analysis/"
    },
    {
     "text": "CAPR Capricor Therapeutics, Inc. NASDAQ $9.85 +9.44%",
     "url": "https://clearank.com/stock/capr-stock-analysis/"
    },
    {
     "text": "BSX Boston Scientific Corp. NYSE $44.70 +1.54%",
     "url": "https://clearank.com/stock/boston-scientific-bsx/"
    },
    {
     "text": "VKTX Viking Therapeutics, Inc. NASDAQ $28.66 -1.14%",
     "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
    },
    {
     "text": "GILD Gilead Sciences Inc. NASDAQ $170.87 +0.92%",
     "url": "https://clearank.com/stock/gilead-sciences-gild/"
    },
    {
     "text": "MDT Medtronic NYSE $101.59 -1.17%",
     "url": "https://clearank.com/stock/medtronic-mdt/"
    },
    {
     "text": "NVAX Novavax Inc. NASDAQ $10.20 -6.34%",
     "url": "https://clearank.com/stock/novavax-nvax/"
    },
    {
     "text": "VOO vs SPYM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/voo-vs-splg/"
    },
    {
     "text": "IONQ vs QBTS Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/ionq-vs-qbts/"
    },
    {
     "text": "VOO vs VTI Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/voo-vs-vti/"
    }
   ]
  }
 ],
 "faq": [
  {
   "question": "What is the IBRX stock forecast?",
   "answer": "The analysts' median 12-month price target is $14.50, which is 115.0% above the current price of $6.75, with the lowest target at $12.00 and the highest at $16.00 across four analysts. The nearest level below the price is the 52-week low of $1.95. The nearest level above it is the 200-day simple moving average at $7.97."
  },
  {
   "question": "What is the IBRX price target?",
   "answer": "The median 12-month analyst target is $14.50, with the lowest target at $12.00 and the highest at $16.00. The consensus rating from the four covering analysts is Strong Buy. The price of $6.75 sits well below the median target."
  },
  {
   "question": "Is IBRX a buy or sell today?",
   "answer": "All four analysts with a current rating rate ImmunityBio a buy or strong buy, with none holding a hold or sell rating, for a consensus of Strong Buy. CleaRank rates the stock Sell with a score of 39 out of 100. The stock is 22.43% below its 50-day simple moving average and 15.33% below its 200-day average, and its 14-day RSI of 36.6 is in the bearish zone."
  },
  {
   "question": "Why did ImmunityBio stock fall after its latest earnings?",
   "answer": "The stock fell 5.13% in the first session after the November 9, 2026 report, when adjusted EPS of -$0.09 missed the estimate of -$0.05 by 80.00%. The report is the one cited in the news for this move, and the reaction to it was negative."
  },
  {
   "question": "How much revenue is ImmunityBio expected to generate this year?",
   "answer": "Analysts' average revenue estimate for this fiscal year is $226.6M, which they expect to be 100.0% higher than last year. Over the same period, the analysts' average EPS estimate is -$0.92. The company's operating margin is -159.68%, so revenue growth has not yet translated into profit."
  },
  {
   "question": "Have insiders been buying or selling IBRX shares?",
   "answer": "Insiders sold $9.4M of stock across 12 sales over the last 18 months, and made no open-market purchases in that period. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than open-market purchases would be."
  },
  {
   "question": "How volatile is the IBRX stock?",
   "answer": "The typical daily move, measured as the 30-day standard deviation of daily returns, is 6.28%. The stock's beta against the S&P 500 is 0.17, so its moves have been weakly linked to the broad market. The one-year return of 212.27% and the one-month return of -35.82% show how wide the swings have been."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "TEVA",
    "name": "Teva Pharmaceutical Industries Ltd. NYSE",
    "price": "$42.40",
    "change": "-1.33%",
    "url": "https://clearank.com/stock/teva-pharmaceutical-teva/"
   },
   {
    "ticker": "DHR",
    "name": "Danaher Corp. NYSE",
    "price": "$236.11",
    "change": "+0.42%",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "CAPR",
    "name": "Capricor Therapeutics, Inc. NASDAQ",
    "price": "$9.85",
    "change": "+9.44%",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "BSX",
    "name": "Boston Scientific Corp. NYSE",
    "price": "$44.70",
    "change": "+1.54%",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "VKTX",
    "name": "Viking Therapeutics, Inc. NASDAQ",
    "price": "$28.66",
    "change": "-1.14%",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   },
   {
    "ticker": "GILD",
    "name": "Gilead Sciences Inc. NASDAQ",
    "price": "$170.87",
    "change": "+0.92%",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "MDT",
    "name": "Medtronic NYSE",
    "price": "$101.59",
    "change": "-1.17%",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "NVAX",
    "name": "Novavax Inc. NASDAQ",
    "price": "$10.20",
    "change": "-6.34%",
    "url": "https://clearank.com/stock/novavax-nvax/"
   }
  ],
  "comparisons": [
   {
    "ticker": "VOO vs SPYM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/voo-vs-splg/"
   },
   {
    "ticker": "IONQ vs QBTS Comparison",
    "name": "",
    "url": "https://clearank.com/compare/ionq-vs-qbts/"
   },
   {
    "ticker": "VOO vs VTI Comparison",
    "name": "",
    "url": "https://clearank.com/compare/voo-vs-vti/"
   }
  ],
  "Newly Tracked": [
   {
    "ticker": "NVAX",
    "text": "Novavax Inc.",
    "url": "https://clearank.com/stock/novavax-nvax/"
   },
   {
    "ticker": "TEVA",
    "text": "Teva Pharmaceutical Industries Ltd.",
    "url": "https://clearank.com/stock/teva-pharmaceutical-teva/"
   },
   {
    "ticker": "CAH",
    "text": "Cardinal Health, Inc.",
    "url": "https://clearank.com/stock/cardinal-health-cah/"
   },
   {
    "ticker": "BAX",
    "text": "Baxter International Inc.",
    "url": "https://clearank.com/stock/baxter-bax/"
   },
   {
    "ticker": "MTZ",
    "text": "MasTec, Inc.",
    "url": "https://clearank.com/stock/mastec-mtz/"
   }
  ],
  "Top Movers (latest session)": [
   {
    "ticker": "RUN",
    "text": "↓ 10.57%",
    "url": "https://clearank.com/stock/run-stock-analysis/"
   },
   {
    "ticker": "MARA",
    "text": "↑ 10.54%",
    "url": "https://clearank.com/stock/mara-holdings-mara/"
   },
   {
    "ticker": "MOD",
    "text": "↑ 9.87%",
    "url": "https://clearank.com/stock/mod-stock-analysis/"
   },
   {
    "ticker": "OFIX",
    "text": "↓ 9.87%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "WDC",
    "text": "↑ 9.86%",
    "url": "https://clearank.com/stock/western-digital-wdc/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "CAPR",
    "text": "Capricor Therapeutics, Inc.",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "CRSP",
    "text": "CRISPR Therapeutics AG",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "IONS",
    "text": "Ionis",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   },
   {
    "ticker": "LEGN",
    "text": "Legend Biotech",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "MRNA",
    "text": "Moderna, Inc.",
    "url": "https://clearank.com/stock/moderna-mrna/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": [
      "CleaRank Financial AI",
      "CleaRank (Clear Rank)"
     ],
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free, and so is the Free plan of its trading workbench; CleaRank is paid for by yearly Pro and Unlimited subscriptions to that workbench, which combines a trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. It uses no affiliate links and takes no payment from the brokers, prop firms or companies it rates or writes about.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@type": "Place",
      "@id": "https://clearank.com/#place",
      "address": {
       "@type": "PostalAddress",
       "streetAddress": "Beni Berman 2",
       "addressLocality": "Netanya",
       "addressRegion": "Center",
       "postalCode": "4249330",
       "addressCountry": "IL"
      }
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@type": "SoftwareApplication",
      "@id": "https://clearank.com/#app",
      "name": "CleaRank",
      "url": "https://clearank.com/"
     },
     "founder": {
      "@type": "Person",
      "@id": "https://clearank.com/writer/shaundavidb/#person",
      "name": "Shaun David",
      "url": "https://clearank.com/writer/shaundavidb/"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/og/mi/stock/immunitybio-ibrx.png",
     "url": "https://clearank.com/og/mi/stock/immunitybio-ibrx.png",
     "width": "1200",
     "height": "630",
     "caption": "ImmunityBio Inc. (IBRX) analysis by CleaRank",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/immunitybio-ibrx/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": 1,
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": 2,
       "item": {
        "@id": "https://clearank.com/stock/",
        "name": "Stocks"
       }
      },
      {
       "@type": "ListItem",
       "position": 3,
       "item": {
        "@id": "https://clearank.com/stock/immunitybio-ibrx/",
        "name": "ImmunityBio Inc. (IBRX)"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/immunitybio-ibrx/#webpage",
     "url": "https://clearank.com/stock/immunitybio-ibrx/",
     "name": "ImmunityBio (IBRX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-11-09T12:30:44+00:00",
     "dateModified": "2026-11-11T12:46:39+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/og/mi/stock/immunitybio-ibrx.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/immunitybio-ibrx/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/anthony-beachey/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/anthony-beachey/#person",
     "name": "Anthony Beachey",
     "jobTitle": "Financial Journalist",
     "url": "https://clearank.com/writer/anthony-beachey/",
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/immunitybio-ibrx/#richSnippet",
     "headline": "ImmunityBio (IBRX) Stock Forecast & Price Target (2026)",
     "name": "ImmunityBio (IBRX) Stock Forecast & Price Target (2026)",
     "description": "IBRX stock forecast and price target 2026: is ImmunityBio a buy? One of the biotechnology names we cover. Wall Street's median target is $14.50.",
     "datePublished": "2026-11-09T12:30:44+00:00",
     "dateModified": "2026-11-11T12:46:39+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/market-insights/methodology/",
     "about": {
      "@type": "Corporation",
      "name": "ImmunityBio Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "IBRX"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems.",
      "tickerSymbol": "IBRX",
      "sameAs": "https://immunitybio.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/immunitybio-ibrx/#webpage"
     },
     "image": {
      "@type": "ImageObject",
      "url": "https://clearank.com/og/mi/stock/immunitybio-ibrx.png",
      "width": 1200,
      "height": 630
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/immunitybio-ibrx/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is the IBRX stock forecast?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The analysts' median 12-month price target is $14.50, which is 115.0% above the current price of $6.75, with the lowest target at $12.00 and the highest at $16.00 across four analysts. The nearest level below the price is the 52-week low of $1.95. The nearest level above it is the 200-day simple moving average at $7.97."
     }
    },
    {
     "@type": "Question",
     "name": "What is the IBRX price target?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median 12-month analyst target is $14.50, with the lowest target at $12.00 and the highest at $16.00. The consensus rating from the four covering analysts is Strong Buy. The price of $6.75 sits well below the median target."
     }
    },
    {
     "@type": "Question",
     "name": "Is IBRX a buy or sell today?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "All four analysts with a current rating rate ImmunityBio a buy or strong buy, with none holding a hold or sell rating, for a consensus of Strong Buy. CleaRank rates the stock Sell with a score of 39 out of 100. The stock is 22.43% below its 50-day simple moving average and 15.33% below its 200-day average, and its 14-day RSI of 36.6 is in the bearish zone."
     }
    },
    {
     "@type": "Question",
     "name": "Why did ImmunityBio stock fall after its latest earnings?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The stock fell 5.13% in the first session after the November 9, 2026 report, when adjusted EPS of -$0.09 missed the estimate of -$0.05 by 80.00%. The report is the one cited in the news for this move, and the reaction to it was negative."
     }
    },
    {
     "@type": "Question",
     "name": "How much revenue is ImmunityBio expected to generate this year?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Analysts' average revenue estimate for this fiscal year is $226.6M, which they expect to be 100.0% higher than last year. Over the same period, the analysts' average EPS estimate is -$0.92. The company's operating margin is -159.68%, so revenue growth has not yet translated into profit."
     }
    },
    {
     "@type": "Question",
     "name": "Have insiders been buying or selling IBRX shares?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insiders sold $9.4M of stock across 12 sales over the last 18 months, and made no open-market purchases in that period. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than open-market purchases would be."
     }
    },
    {
     "@type": "Question",
     "name": "How volatile is the IBRX stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The typical daily move, measured as the 30-day standard deviation of daily returns, is 6.28%. The stock's beta against the S&P 500 is 0.17, so its moves have been weakly linked to the broad market. The one-year return of 212.27% and the one-month return of -35.82% show how wide the swings have been."
     }
    }
   ]
  }
 ]
}